MUK <i>nine</i> OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia
Sarah Brown(University of Leeds), Martin Kaiser(Royal Marsden NHS Foundation Trust), Guy Pratt(University Hospitals Birmingham NHS Foundation Trust), Debbie Sherratt(University of Leeds), Katrina Walker(University of Leeds), Sadie Roberts(University of Leeds), Andrew Hall(University of Leeds), Matthew Jenner(University Hospital Southampton NHS Foundation Trust), Louise Flanagan(University of Leeds), Samantha Hinsley(University of Leeds), Christina Messiou(Institute of Cancer Research)
Cited by 27
Related Papers
Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial
|The Lancet|2010|640
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
|Journal of Clinical Oncology|2015|564
Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2021|558